-Data Release Announced Today at White House Precision Medicine
CAMBRIDGE, Mass., & WASHINGTON--(BUSINESS WIRE)--
Medicine, Inc. (NASDAQ:FMI) today announced that the company will
release to the public molecular profiles of pediatric cancers currently
maintained as part of FoundationCore™, the company's information
knowledgebase. FoundationCORE is one of the largest and most robust
collections of common and rare clinical tumor profiles globally. The
release of this data is part of the company's ongoing effort to
stimulate and accelerate research and development of much needed
precision oncology therapies to treat all cancers, including pediatric
cancers. The announcement of the data release, which is the
first-of-its-kind from FoundationCORE, was announced today at the
Precision Medicine Initiative Summit held at the White House.
"One of the biggest impediments to progress in the field of childhood
cancer is the paucity of genomic data available from patients at the
time of disease relapse. These data are critical to defining
comprehensive strategies to precisely treat relapsed disease, and more
importantly, to prevent disease recurrence in the first place," stated
John M. Maris, M.D., Giulio D'Angio Endowed Professor of Pediatric
Oncology at Children's Hospital of Philadelphia and Perelman School of
Medicine at the University of Pennsylvania. "The data being made
available from Foundation Medicine will serve as a tremendous resource
for the cancer research community and should catalyze the process of
bringing effective new therapies to children with cancer."
FoundationCORE is a molecular information knowledgebase that contains
genomic information and insights from more than 68,000 adult and
pediatric patients whose tumors were profiled by Foundation Medicine.
FoundationCORE is continuously evolving over time, informed by every new
tumor sequenced with the company's clinical comprehensive genomic
profiling assays, FoundationOne® and FoundationOne®
Heme. Foundation Medicine is developing a web-based HIPPA-compliant
portal for public access to the de-identified, molecular-level pediatric
tumor information contained in FoundationCORE. The portal is expected to
be accessible for public access by March 31st.
"The proposed release of data by Foundation Medicine is a major advance
towards achieving our nation's precision medicine initiatives,
particularly in an area of significant unmet need for children," said
Nancy Goodman, executive director, Kids v Cancer. "This type of
out-of-the-box initiative gives great hope to the families and patients
who need it most. We're looking forward to the renaissance in targeted
and immunotherapies for children that may come as a result of this data."
Pediatric cancers are a rare and diverse collection of diseases. While
childhood and adolescent cancer is rare, it remains the leading cause of
death by disease among children. The American Cancer Society predicted
that about 10,380 children in the United States would be diagnosed with
cancer in 2015 and childhood cancer rates have been rising slightly for
the past few decades.1 The data set being released from
FoundationCORE offers robust opportunities for researchers, and can be
used to generate hypotheses, validate rare findings and investigate the
genomic landscape of rare tumors for which only small studies exist.
Data from thousands of tumors will be publicly available without cost to
the research community for exploration and incorporation into future
experiments that will ultimately improve the treatment and prognosis for
children with cancer.
"There are few things in life as devastating as when a child is
diagnosed with cancer. It's critically important to the achievement of
our corporate mission that the robust genomics information we have
amassed is freely and easily accessible to researchers and utilized as
an important tool to address the significant unmet medical need in
pediatric cancers," said Michael Pellini, M.D., chief executive officer,
Foundation Medicine. "We are extremely proud to be in a position that
enables us to foster global collaborations among researchers by
providing anywhere, anytime access to rich molecular information in an
easy to use format. In doing so, we hope to accelerate the pace of
innovation in pediatric cancer with the intent of bringing new,
potentially lifesaving therapeutics to children."
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information company
dedicated to a transformation in cancer care in which treatment is
informed by a deep understanding of the genomic changes that contribute
to each patient's unique cancer. The company's clinical assays,
FoundationOne® for solid tumors and FoundationOne® Heme for hematologic
malignancies and sarcomas, provide a comprehensive genomic profile to
identify the molecular alterations in a patient's cancer and match them
with relevant targeted therapies and clinical trials. Foundation
Medicine's molecular information platform aims to improve day-to-day
care for patients by serving the needs of clinicians, academic
researchers and drug developers to help advance the science of molecular
medicine in cancer. For more information, please visit http://www.FoundationMedicine.com
or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne®
are registered trademarks, and FoundationCORE™ is a trademark, of
Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. All
such forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include the risks that the
release of pediatric data by Foundation Medicine may not occur as
anticipated, may be delayed or may not occur at all; that the electronic
portal for such pediatric data may not be accessible; that the pediatric
data may not be as robust as anticipated or may not generate additional
research and development opportunities; and the risks described under
the caption "Risk Factors" in Foundation Medicine's Quarterly Report on
Form 10-Q for the quarter ended March 31, 2015, which is on file with
the Securities and Exchange Commission, as well as other risks detailed
in Foundation Medicine's subsequent filings with the Securities and
Exchange Commission. All information in this press release is as
of the date of the release, and Foundation Medicine undertakes no duty
to update this information unless required by law.
1American Cancer Society, www.cancer.org
View source version on businesswire.com: http://www.businesswire.com/news/home/20160225005087/en/
Dan Budwick, Pure Communications, Inc.
Source: Foundation Medicine, Inc.
News Provided by Acquire Media